20 November 2012
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
Exercise of Options
Allergy Therapeutics plc (AIM: AGY), the fully integrated speciality pharmaceutical company specialising in allergy vaccines, announces it has made an application to the London Stock Exchange for 1,400,000 ordinary shares of 0.1p each to be admitted to trading on AIM. Dealing is expected to commence on 21 November 2012. The ordinary shares have been allotted pursuant to the exercise of options and will rank pari passu in all respects with the existing ordinary share capital of the Company. The total number of shares in issue (inclusive of the above issue) is 418,161,314 ordinary shares of 0.1p each.
-Ends-
For further information
Allergy Therapeutics |
+44 (0) 1903 845 820 |
Manuel Llobet, Chief Executive Officer |
|
|
|
Nomura Code Securities |
+44 (0) 207 776 1200 |
Juliet Thompson/ Clare Terlouw |
|